A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

NCT01578499 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Cutaneous Anaplastic Large Cell Lymphoma
Mycosis Fungoides
Cutaneous T-Cell Lymphoma

Interventions

DRUG: Brentuximab Vedotin
DRUG: Methotrexate
DRUG: Bexarotene

Sponsor

Millennium Pharmaceuticals, Inc.

Collaborators

[object Object]